China Nuokang Bio-Pharmaceutical Inc. Appoints David Gao to Board of Directors
December 20 2011 - 9:00AM
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or
the "Company"), a leading China-based biopharmaceutical company
focused on the research, development, manufacture, marketing and
sales of hospital-based medical products, today announced that Mr.
David Xiaoying Gao was appointed to the Company's board of
directors ("the Board") and as a member of the audit committee and
corporate governance & nominating committee, effective on
December 19, 2011. Mr. Gao will be replacing Mr. William Keller,
who is leaving the Board for personal reasons.
Mr. Gao served as the chief executive officer and a director of
BMP Sunstone (Nasdaq:BJGP) from February 2004 until its acquisition
by Sanofi-aventis in February 2011. Following the acquisition, he
transitioned to become a senior integration advisor for
Sanofi-aventis from February 2011 to August 2011. Previously, Mr.
Gao served as chairman of the board of directors and CEO of Abacus
Investments Ltd, a private wealth management company, and also held
various executive positions at Motorola, Inc. including
vice-president and director of the integrated electronic system
sector, Asia-Pacific operations; and served as a member of the
management board of Motorola Asia Pacific, Motorola Japan Ltd. and
Motorola China.
Mr. Gao holds a B.S. in mechanical engineering from the Beijing
Institute of Technology, a M.S. in mechanical engineering from
Hanover University in Germany and an M.B.A. from the Massachusetts
Institute of Technology. Mr. Gao also currently serves as an
independent director for China Biologic Products Inc
(Nasdaq:CBPO).
Mr. Baizhong Xue, the Company's chairman and chief executive
officer, stated, "We would like to begin by thanking William for
his contributions over the past few years. We wish him the best
moving forward. We are also excited to welcome David to our board.
We believe his experience in building BMP Sunstone into a
China-based pharmaceutical company with over a hundred million
dollars in annual sales will contribute to Nuokang's future growth
prospects. Furthermore, we believe his diverse expertise in
the various stages of a corporation's development garnered from
completing and integrating a multinational acquisition and serving
as an independent director of a fellow U.S.-listed, China-based
peer is invaluable."
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading
biopharmaceutical company in China focused on the research,
development, manufacture, marketing and sales of hospital-based
medical products. The Company provides a diversified portfolio of
products across more than 3,000 hospitals in China. Nuokang's
principal products include Baquting®, China's leading hemocoagulase
product by market share, and Kaitong®, a lipid emulsion alprostadil
product for the treatment of peripheral vascular diseases,
cardiocerebral microcirculation disorders and post-surgery
thrombosis. The Company's product pipeline includes product
candidates under development in hematological, cardiovascular and
cerebrovascular disease diagnosis, treatment and prevention. Please
visit www.nkbp.com for more information.
Safe-Harbor Statement
This press release contains statements of a forward-looking
nature. These statements, including the statements relating to the
Company's growth prospects, are made under the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including certain plans, expectations, goals, and projections,
which are subject to numerous assumptions, risks, and
uncertainties. These forward-looking statements may include, but
are not limited to, statements containing words such as "will,"
"future" and "believe" or similar expressions. These
forward-looking statements speak only as of the date of this press
release and are subject to change at any time. These
forward-looking statements are based upon management's current
expectations and are subject to a number of risks, uncertainties
and contingencies, many of which are beyond the Company's control
that may cause actual results, levels of activity, performance or
achievements to differ materially from any future results, levels
of activity, performance or achievements expressed or implied by
such forward-looking statements.
CONTACT: ICR, Inc.
In the U.S.: Ashley De Simone: 1-646-277-1227
In China: Wen Lei Zheng: 86-10-6583-7510
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024